BYOOVIZ®
Search documents
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe
Businesswire· 2026-01-02 07:00
Core Viewpoint - Samsung Bioepis has commenced the direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe [1] Company Summary - Samsung Bioepis is actively entering the European market with its biosimilar product BYOOVIZ® [1]
Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval
Businesswire· 2025-12-02 06:00
INCHEON, Korea--(BUSINESS WIRE)-- #amd--Samsung Bioepis' Byooviz PFS gains European approval. ...
